UpdatesPress Release
Orchid Pharma partnered with Pharmasyntez JSC via a licensing and supply agreement for its novel antibiotic, Exblifep®, in Russia.
Orchid Pharma LimitedORCHPHARMA · Filed with the exchange
Orchid will supply finished dosage, with Pharmasyntez holding commercialization rights.
This presents a potential USD 178 million opportunity over 10 years.
No comments yet. Be the first.